Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mazzacurati

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Oncogene|December 17, 2002
GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activityShunqian Jin, Tong Tong, Wenhong Fan, et al.
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy|August 4, 2022
Spectroscopic and quantum mechanical study of a scavenger molecule: N,N-diethylhydroxylamineGiovanna Salvitti, Emanuele Pizzano, Filippo Baroncelli, et al.
Oncogene|October 19, 2002
ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growthFeiyue Fan, Shunqian Jin, Sally A Amundson, et al.
Blood Advances|November 15, 2019
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPNLucia Mazzacurati, Robert J Collins, Garima Pandey, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
Controlling treatment toxicity in ovarian cancer to prime the patient for tumor extinction therapyKit Gallagher, Rachel S Sousa, Chandler Gatenbee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 10, 2014
Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSVLucia Mazzacurati, Marco Marzulli, Bonnie Reinhart, et al.
American Journal of Hematology|March 5, 2024
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasmsGarima Pandey, Lucia Mazzacurati, Tegan M Rowsell, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 17, 2012
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virusHiroaki Uchida, Marco Marzulli, Kenji Nakano, et al.
Neoplasia (New York, N.Y.)|October 10, 2024
Corrigendum to "Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells" [Neoplasia 17 (2014) 85]Rajendra P Gajula, Sivarajan T Chettiar, Russell D Williams, et al.
Neoplasia (New York, N.Y.)|January 28, 2015
Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cellsRajendra P Gajula, Sivarajan T Chettiar, Russell D Williams, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Oncogene|December 17, 2002
GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activityShunqian Jin, Tong Tong, Wenhong Fan, et al.
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy|August 4, 2022
Spectroscopic and quantum mechanical study of a scavenger molecule: N,N-diethylhydroxylamineGiovanna Salvitti, Emanuele Pizzano, Filippo Baroncelli, et al.
Oncogene|October 19, 2002
ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growthFeiyue Fan, Shunqian Jin, Sally A Amundson, et al.
Blood Advances|November 15, 2019
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPNLucia Mazzacurati, Robert J Collins, Garima Pandey, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
Controlling treatment toxicity in ovarian cancer to prime the patient for tumor extinction therapyKit Gallagher, Rachel S Sousa, Chandler Gatenbee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 10, 2014
Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSVLucia Mazzacurati, Marco Marzulli, Bonnie Reinhart, et al.
American Journal of Hematology|March 5, 2024
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasmsGarima Pandey, Lucia Mazzacurati, Tegan M Rowsell, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 17, 2012
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virusHiroaki Uchida, Marco Marzulli, Kenji Nakano, et al.
Neoplasia (New York, N.Y.)|October 10, 2024
Corrigendum to "Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells" [Neoplasia 17 (2014) 85]Rajendra P Gajula, Sivarajan T Chettiar, Russell D Williams, et al.
Neoplasia (New York, N.Y.)|January 28, 2015
Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cellsRajendra P Gajula, Sivarajan T Chettiar, Russell D Williams, et al.
Pageof 6